Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 September 2014Website:
http://eledon.comNext earnings report:
28 March 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 16 min agoDividend
Analysts recommendations
Institutional Ownership
ELDN Latest News
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants
Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation 80 participants (two-thirds of projected recruitment) enrolled in Phase 2 BESTOW trial Completed an oversubscribed $50 million private placement; Company expects sufficient liquidity through December 2025 IRVINE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported recent business highlights for its second quarter 2024.
Penny stocks sometimes get a bad rep due to their inherent risk. They are cheap but are considered highly volatile and have a low chance of providing substantial profit.
Data from 13 participants presented at the American Transplant Congress continue to support safety and tolerability profile of tegoprubart Overall mean eGFR of all reported time points after day 30 post-transplant of 70.5 mL/min/1.73m² Mean eGFR measured above 60 mL/min/1.73m ² at all reported time points after day 30 post-transplant IRVINE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today presented updated data from the Company's ongoing open-label Phase 1b trial and open-label extension study evaluating tegoprubart for the prevention of organ rejection in kidney transplant patients.
Eledon Pharmaceuticals (ELDN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Does Eledon Pharmaceuticals, Inc. (ELDN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Eledon Pharmaceuticals (ELDN) could see an increase in its stock price due to increasing confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Paul Little - Chief Financial Officer David-Alexandre Gros - Chief Executive Officer Steve Perrin - President and Chief Scientific Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Thomas Smith - SVB Securities Rami Katkhuda - LifeSci Capital Vernon Bernardino - H.C. Wainwright Raymond Wu - Ladenburg Thalmann Operator Good afternoon, ladies and gentlemen and welcome to Eledon Pharmaceuticals first quarter 2023 earnings conference call.
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Paul Little - Chief Financial Officer David-Alexandre Gros - Chief Executive Officer Steven Perrin - President and Chief Scientific Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Thomas Smith - SVB Leerink Securities Matt Kaplan - Ladenburg Thalmann Rami Katkhuda - LifeSci Capital Operator Greetings, and welcome to the Eledon Pharmaceuticals Fourth Quarter and Full-Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
What type of business is Eledon Pharmaceuticals?
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
What sector is Eledon Pharmaceuticals in?
Eledon Pharmaceuticals is in the Healthcare sector
What industry is Eledon Pharmaceuticals in?
Eledon Pharmaceuticals is in the Biotechnology industry
What country is Eledon Pharmaceuticals from?
Eledon Pharmaceuticals is headquartered in United States
When did Eledon Pharmaceuticals go public?
Eledon Pharmaceuticals initial public offering (IPO) was on 17 September 2014
What is Eledon Pharmaceuticals website?
https://eledon.com
Is Eledon Pharmaceuticals in the S&P 500?
No, Eledon Pharmaceuticals is not included in the S&P 500 index
Is Eledon Pharmaceuticals in the NASDAQ 100?
No, Eledon Pharmaceuticals is not included in the NASDAQ 100 index
Is Eledon Pharmaceuticals in the Dow Jones?
No, Eledon Pharmaceuticals is not included in the Dow Jones index
When was Eledon Pharmaceuticals the previous earnings report?
No data
When does Eledon Pharmaceuticals earnings report?
The next expected earnings date for Eledon Pharmaceuticals is 28 March 2025